Multidisciplinary Approach to Treating Advanced Endometrial Cancer

Video Transcription

Video Summary

In this webinar titled "Multidisciplinary Approach to Treating Advanced Endometrial Cancer," the co-chair, Flora Backus, welcomes the participants and introduces the faculty, which includes gynecologic oncologists and a pharmacist. The webinar discusses the approval of the combination of Lenbatinib and Pembrolizumab for the treatment of advanced endometrial cancer. The faculty provides important data on the treatment regimen and highlights the effectiveness of the combination in terms of progression-free survival, overall survival, objective response rates, and duration of response. They also discuss common side effects such as hypertension, hypothyroidism, diarrhea, and rash, and provide tips on managing these side effects. The importance of patient education and close monitoring is emphasized, and the faculty suggests strategies for managing side effects, including lifestyle modifications, medication adjustments, and timely interventions. The webinar concludes with a Q&A session, where the faculty addresses questions from participants. The recording of the webinar will be available on the IGCS Education 360 Learning Portal. No credits were mentioned in the transcript.

Keywords

Multidisciplinary Approach

Treating Advanced Endometrial Cancer

Lenbatinib

Pembrolizumab

Combination Therapy

Progression-free Survival

Overall Survival

Objective Response Rates